3 Drugs Johnson & Johnson’s Investors Better Know About

Johnson & Johnson's sales grew 3.5% during the past year, but only because of big sales growth from a handful of its recently launched drugs. Among these fast-growing new drugs are Johnson's next-generation treatment for diabetes, a new anticoagulant that's displacing warfarin's decades long market share leadership, and a multi-billion dollar drug for tough-to-treat prostate cancer.

However, all three of these drugs are facing challenges that may threaten their market share. Competitors, including AstraZeneca (NYSE: AZN  )  Pfizer (NYSE: PFE  ) , Medivation  (NASDAQ: MDVN  ) , and Astellas (NASDAQOTH: ALPMY  ) are lining up to try and capture Johnson's market share in these indications.

In the following slideshow, you'll learn what these three drugs are, which companies are challenging their dominance, and seven important questions you should be asking about them this year. 

Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

 


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2920368, ~/Articles/ArticleHandler.aspx, 9/2/2014 1:45:05 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 17,020.20 -78.25 -0.46%
S&P 500 1,995.02 -8.35 -0.42%
NASD 4,579.86 -0.41 -0.01%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/2/2014 10:19 AM
ALPMY $14.49 Up +0.08 +0.56%
ASTELLAS PHARMA UN… CAPS Rating: No stars
AZN $74.69 Down -1.32 -1.74%
AstraZeneca plc (A… CAPS Rating: ***
MDVN $90.38 Down -0.88 -0.96%
Medivation, Inc. CAPS Rating: **
PFE $29.28 Down -0.12 -0.39%
Pfizer CAPS Rating: ****

Advertisement